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Abstract
Background: Management of diabetes through improved glycemic control and risk factor modification can help
prevent long-term complications. Much diabetes management is self-management, in which healthcare providers
play a supporting role. Well-designed e-Health solutions targeting behavior change can improve a range of measures,
including glycemic control, perceived health, and a reduction in hospitalizations.
Methods: The primary objective of this study is to evaluate if a mobile application designed to improve self-management
among patients with type 2 diabetes (T2DM) improves glycemic control compared to usual care. The secondary objectives
are to determine the effects on patient experience and health system costs; evaluate how and why the intervention
worked as observed; and gain insight into considerations for system-wide scale-up. This pragmatic,
randomized, wait-list-control trial will recruit adult participants from three Diabetes Education Programs in
Ontario, Canada. The primary outcome is glycemic control (measured by HbA1c). Secondary outcomes
include patient-reported outcomes and patient-reported experience measures, health system utilization, and
intervention usability. The primary outcome will be analyzed using an ANCOVA, with continuous secondary
outcomes analyzed using Poisson regression. Direct observations will be conducted of the implementation
and application-specific training sessions provided to each site. Semi-structured interviews will be conducted with
participants, healthcare providers, organizational leaders, and system stakeholders as part of the embedded process
evaluation. Thematic analysis will be applied to the qualitative data in order to describe the relationships between (a)
key contextual factors, (b) the mechanisms by which they effect the implementation of the intervention, and (c) the
impact on the outcomes of the intervention, according to the principles of Realist Evaluation.
Discussion: The use of mobile health and virtual tools is on the rise in health care, but the evidence of their
effectiveness is mixed and their evaluation is often lacking key contextual data. Results from this study will provide
much needed information about the clinical and cost-effectiveness of a mobile application to improve diabetes
self-management. The process evaluation will provide valuable insight into the contextual factors that influence the
application effectiveness, which will inform the potential for adoption and scale.
(Continued on next page)
* Correspondence: sacha.bhatia@wchospital.ca
1Women’s College Hospital Institute for Health Systems Solutions and Virtual Care,
Women’s College Hospital, 76 Grenville Ave, Toronto, ON M5S 1B2, Canada
2Women’s College Research Institute, Women’s College Hospital, 76 Grenville
Ave, Toronto, ON, Canada
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Desveaux et al. BMC Medical Informatics and Decision Making  (2016) 16:144 
DOI 10.1186/s12911-016-0381-5
(Continued from previous page)
Trial registration: Clinicaltrials.gov NCT02813343. Registered on 24 June 2016 (retrospectively registered).
Trial Sponsor: Ontario Telemedicine Network
Keywords: E-Health, Randomized controlled trial, Diabetes, Self-management, Implementation science, Mobile health
Background
E-Health solutions are increasingly common in health-
care, and involve the use of an electronic device or mon-
itoring system by individuals or their healthcare
providers to monitor or improve their health status [1].
Well-designed e-Health solutions for diabetes manage-
ment targeting health behaviour change can improve a
range of measures, including improvements in glycemic
control, perceived health, and a reduction in hospitaliza-
tions [2, 3]. Furthermore, e-Health has been shown to
streamline communication among providers and enable
the provision of care by providing providers with
improved knowledge, skills, and confidence [4]. Most
notably, these solutions may provide an opportunity to
improve access to enhanced care for marginalized popu-
lations and may be cost-effective to implement at scale.
An obvious area in which e-Health holds potential is
the management of Type 2 Diabetes (T2DM). The global
prevalence of diabetes continues to rise, with projections
estimating 9 % of the population will be impacted by
2035 [5]. In Canada alone, over 2.4 million individuals
are living with diabetes, with anticipated increase in
prevalence to 3.7 million Canadians by 2018 [6].
Diabetes is the leading cause of adult blindness [7] and
end stage renal disease among Canadians [8], with the
cost of care for individuals with diabetes currently reach-
ing 3–4 times that of those without the disease [6].
Management of diabetes through improvements in gly-
cemic control [9] and risk factor modification can help
prevent long-term complications [10]. Unfortunately,
evidence-to-practice gaps are well documented in diabetes
care [11]. In addition, much of the management of dia-
betes lies not in the hands of health care providers, but in
the day-to-day self-management of the millions of people
living with this chronic condition whose lives are complex
and not solely defined by the disease. This reality drives
the increasing interest in innovative strategies to improve
self-management that emphasizes convenience and recog-
nizes the realities of people’s busy lives. Although the use
of mobile interventions to improve diabetes self-
management significantly improved glycaemic control
[12], substantially heterogeneity in intervention design
and implementation continues to be a reality [3]. Among
successful interventions, the most common behaviour
change techniques include prompt self-monitoring and
feedback on performance [3]- features that are easily in-
corporated as part of mobile technology.
In light of the evidence, health system decision makers
in Ontario, Canada are interested in evaluating the
effectiveness, implementation, and impact of mobile-
based self-management tools for T2DM among diverse
patient populations throughout the province. Lessons
learned are likely to be useful across a wide variety of
chronic conditions and therefore have significant poten-
tial to address the triple aim of improved population
health outcomes, enhanced patient experience and
reduced health care costs per capita. This pragmatic
evaluation will explore not only whether the intervention
produces an effect, but how and why this effect (or lack
thereof ) is produced.
The primary objective of this study is to evaluate
whether a mobile application designed to improve self-
management and experience of care can improve clinical
outcomes compared to usual care for people with
T2DM. The secondary objectives are to determine the
effects on patient experience and health system costs; to
evaluate how and why the intervention worked as
observed; and to gain insight into considerations for
system-wide scale-up. The inclusion of the embedded
process evaluation within the overall study design pre-
sents a novel contribution in the e-Health literature by
including a methodological approach to provide insight
into how e-Health tools function more generally, beyond
their application to diabetes care. The project evaluation
is based on a model of integrated knowledge translation
[13], whereby the health system decision makers, imple-
mentation leads, and scientific evaluators have collabo-
rated to inform the development of the research project
from the outset.
Methods
We designed a pragmatic, randomized, wait-list-
control trial with an embedded qualitative process
evaluation to evaluate whether and how a mobile
application designed to improve self-management and
experience of care among patients with T2DM has an
effect on clinical outcomes and healthcare utilization.
The protocol received ethics approval from Research
Ethics Boards at participating institutions, including
Women’s College Hospital, St. Joseph’s Care Group,
North York General Hospital, and William Osler
Health System. The trial is registered on Clinical-
Trials.gov (NLM Identifier: NCT02813343).
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Setting
Most health services in Ontario, Canada are financed
through the publicly-funded Ontario Health Insurance
Program (OHIP). OHIP covers medically necessary
services provided by physicians, including primary care,
emergency services, inpatient medical services, and spe-
cialist visits. In addition to OHIP, the Ministry of Health
& Long-Term Care funds Diabetes Education Programs
(DEPs), which are community-based, multi-disciplinary
programs accessible through both physician and self-
referral. DEPs provide diabetes education services for
clients who are aged 18 or over. Their primary focus is
the provision of diabetes education and management
services for individuals diagnosed with diabetes or pre-
diabetes according to the Canadian Diabetes Association
Guidelines [14]. This includes education around self-
monitoring blood glucose levels, screening for complica-
tions, nutrition, physical activity, and appropriate
management strategies including vascular protection,
and optimizing glycemic control.
Participating DEPs were selected by the Ontario
Telemedicine Network (OTN) and include the Diabetes
Health Centre in Thunder Bay, the Diabetes Education
Center at North York General Hospital, and two
Diabetes Education Centers belonging to the William
Osler Health System. OTN reached out to the Provincial
Chronic Disease Management-Local Health Integration
Leads Council for help in identifying organizations who
would be good partners in this initiative. These sites
serve a socially and ethnically diverse range of patients
with diabetes, representing more than 4500 Ontarians
annually. Each site serves distinct populations, including
a large aboriginal population in Thunder Bay and visible
minorities and new immigrants in the William Osler
Health System.
Stakeholders
The intervention will be implemented by the OTN, a
non-profit, government funded organization and the lar-
gest provider of telemedicine services in the province of
Ontario [15]. OTN’s involvement in an advisory capacity
increases the likelihood that the study results will have a
future impact on health system policy. This engages the
principles of integrated knowledge translation to collab-
oratively produce knowledge [16], with the aim of
optimizing health care delivery and associated clinical out-
comes. The study is funded by Canada Health Infoway.
Trial design
The study is a pragmatic, randomized, wait-list-control
trial with blinded outcome assessment. It is important to
note that the study design reflects an external, third-
party evaluation. The evaluation team is independent
from both the application vendor and the implementation
team, which is coordinated and controlled by OTN. A
pragmatic randomized trial design was chosen because it
is a methodology that guides the assessment of whether
an intervention works when introduced into a public
health or clinical setting (i.e., in real-life conditions).
Participants are randomized into one of two groups: an
immediate treatment group (ITG) and a wait-list-control
(WLC) group. The ITG group immediately begins using
the application (e-Health intervention), for a total dur-
ation of six months (refer to Fig. 1). The WLC group
receives usual care for the first three months, at which
point they will cross over to the intervention arm and use
the application for a total of 3 months.
Eligibility
Patients are eligible for inclusion into the study if they
meet the following criteria: 1) adults over the age of 18;
2) obtaining care for T2DM at a participating DEP; 3)
HbA1c ≥ 8.0 % (and at least 1 % above the participant’s
target level) on most recent laboratory report within the
last 3 months 4) currently using an active email address
or able and willing to obtain one; and 5) able to read the
English language (self-reported). Patients are excluded if
they have Type 1 diabetes; are on continuous glucose
monitoring; have an insulin pump; are on dialysis; are
Fig. 1 Flow of Participants
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pregnant; or are unable to use a computer or mobile
phone due to severe mental or physical impairment. The
inclusion criteria are intentionally broad to align with
the objectives of pragmatic trial design to determine
whether the application works under usual conditions to
promote generalizability [17]. The diagnostic exclusion
criteria reflect a set of conditions in which there are dis-
tinct and unique self-management needs, which the ap-
plication is not currently designed to address.
Recruitment
Participants are recruited from participating DEPs asso-
ciated with three institutions across Ontario. A clinician
at each site identifies potential eligible participants dur-
ing their regularly scheduled clinical appointment. Inter-
ested individuals meet with a site coordinator who
provides them with an information brochure and a con-
sent form to review. Interested participants contact the
research assistant using the dedicated study phone line.
The research assistant obtains and documents verbal in-
formed consent and collects baseline outcome measures
(refer to Fig. 2, Part A). Participants are then random-
ized to one of the study arms. Following randomization,
the site coordinator collects clinical information (refer to
Fig. 2, Part B) and provides participants in the ITG with
a study-specific mobile phone. Participants enter initial
clinical information into the application (medications,
etc.) while in clinic and the data is reviewed for accuracy
by a clinician (nurse, nurse practitioner, or certified dia-
betes educator). Participants in the WLC group receive
their application-enabled phone in person following
completion of the control phase (three months after
enrollment).
OTN has partnered with Samsung to provide a total of
300 smartphones with the mobile health application pre-
loaded. Each device will be connected to the Telus mo-
bile network in addition to having the ability to connect
to wireless networks. As all phones need to be distrib-
uted as part of the partnership, a targeted sample of 300
patients will be recruited.
Allocation
Randomization is centralized, web-based and generated
by the Applied Health Research Centre (AHRC) at the
Li Ka Shing Knowledge Institute of St. Michael’s
Hospital. Randomization is stratified by site using ran-
domly permuted blocks of varying sizes, which are not
known by the study team.
Once the participant has been enrolled and the base-
line assessments are completed, randomization occurs in
REDCap™, a web-based electronic data entry system,
where the participant is automatically assigned a group
allocation (ITG or WLC).
Interventions
Mobile Application (E-Health Intervention) The inter-
vention is a commercially available mobile application
that is designed to serve as a virtual coach for patients
with T2DM. The application allows participants to enter
a range of baseline clinical information, in addition to
ongoing data related to diabetes management, including
blood glucose values, daily medications, food intake, and
activity levels (https://www.bluestardiabetes.com/). The
application analyzes inputted data to provide tailored
messaging to ‘coach’ participants with respect to their
diabetes management. Coaching is a process of continu-
ous improvement involving education regarding targets,
negotiating a plan of action to achieve the target, and
subsequent monitoring of the patient’s progress toward
achievement of the target [18, 19]. Lifestyle coaching
empowers participants by giving them the knowledge
and skills to work in partnership with providers to
achieve health goals [18, 19]. The mobile application
has been shown in other contexts and settings to be
effective at teaching patients with T2DM about diet-
ary impacts on their blood glucose levels, encouraging
patients to generate higher-quality blood glucose data
for enhanced self-monitoring, and to improve gly-
cemic control as represented by reduction in levels of
HbA1c [20, 21].
The intervention is believed to improve disease control
through two patient-mediated processes: tailored messa-
ging and education and facilitated relay of information
from the patient to their healthcare provider [22]. The
application provides customized, real-time, evidence-
based messages based on the Trans-Theoretical Model
of Behaviour Change [23] that impact patient motiv-
ation, behaviour and education. Educational messages
are organized along the American Association of
Diabetes Educators 7 Standards of Care [24] and are
supported by a library of educational videos that patient
can access at any time. The application also facilitates
the transfer of disease monitoring data to their primary
care provider via a Smart Visit report. The application
reminds participants to print this document and bring it
to clinical appointments, although the option is available
to print the report on demand.
Usual Care Usual care at DEPs are intended to provide
multi-disciplinary self-management support to patients
with diabetes and may include interactions with a
diabetes educator (nurse, nurse practitioner, dietician,
pharmacist) or physician specializing in diabetes care.
These clinics are designed to support the efforts of the
primary care provider, and are not intended to be a sub-
stitution for this ongoing relationship. The duration of a
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Fig. 2 Case Report Form
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patient’s affiliation with a DEP can be highly variable
based on clinic, patient and disease factors.
Data collection
Baseline information including demographics and health
status will be collected using an electronic case report
form (CRF) (refer to Fig. 2). HbA1c values will be re-
corded at baseline, 3 months, and 6 months. Participants
who do not have a recent value within two weeks of the
study assessment will be given a requisition to perform
blood work during the first study visit. Baseline informa-
tion will be collected by a research assistant via a tele-
phone call, after which the participant will be formally
enrolled in the study. Participants who fail to complete
the baseline assessment will not be enrolled. Follow up
data will be collected using a secure online questionnaire
administered via REDCap™ that can be completed by
participants from any device with an internet browser
and connection (computer, tablet etc.). Weekly reminders
will be sent to participants who fail to complete the ques-
tionnaire, with a maximum of three reminders. Partici-
pants who express a preference for phone communication
will be contacted by the research assistant, following the
same reminder protocol. Application utilization data is
tracked directly through the application and will be
extracted at the end of the study.
Healthcare utilization and cost outcome measures will
be obtained from health administrative data available
through the Institute for Clinical Evaluative Sciences
(ICES). At the time of study enrolment, patients will be
asked to provide consent to link their OHIP number to
health administrative data. ICES is a non-profit research
institute with a secure and expansive repository of
Ontario’s health-related administrative data from hos-
pital, physician, long term care and other related health
services paid for by the provincial health insurance plan.
These data are linked using encrypted identifiers. Data
from this study will be linked to ICES data using
encrypted health card identifiers created by ICES autho-
rized personnel. ICES is a prescribed entity and data
custodian under the Personal Health Information Pro-
tection Act (PHIPPA).
Outcomes
The primary outcome measurement is glucose control,
measured by HbA1c at 3 months. Secondary outcomes
which will be evaluated at 3 months are patient-reported
outcomes measures (PROMs) and patient-reported
experience measures (PREMs), which include data on
health system utilization using composites of items from:
the Commonwealth Fund Survey for Patients with Com-
plex Needs; the Canadian Institutes of Health Research
Community Based Primary Health Care Survey; and the
EQ5D [25]. Self-efficacy will be measured using two
validated scales: the Problem Areas in Diabetes 5 (PAID 5)
[26] and the Summary of Diabetes Self-care Activities
(SDSCA-6) [27]. All outcomes will be assessed again at
6 months. Intervention usability is an additional secondary
outcome which will be evaluated at the end of study as
measured by an adapted version of the Mobile App Rating
Scale [28] (refer to Fig. 3 for adapted version) and applica-
tion utilization data collected routinely collected through
the application. Utilization measures include the mean
number of engagements per week; mean length of time
engaging with the application per week; and the frequency
of use of each feature per week (e.g., educational tools,
Smart Visit Report, blood sugar monitoring).
In this study, costs of healthcare utilization are used to
measure resource intensity. Table 1 outlines the data-
bases used to assess these costs, which will be used to
determine frequency and intensity of healthcare
utilization and overall individual costs using methods
developed for use with Ontario data [29]. Costs of health
care resource use will be quantified for patients with
algorithms developed for patient-level costing using
health administrative data and implemented at ICES
[29]. Costs for each encounter that generated an
encounter-specific payment (e.g., prescriptions, fee-for-
service physician visits) are measured as the fee paid for
the service. Costs for hospital encounters are determined
using the appropriate resource intensity weight for that
particular care setting and the weighted cost derived
based on Ontario spending. Costs for long-term care are
measured as a fixed per diem based on prevailing gov-
ernment payment rates. Emergency department physi-
cians receive substantial alternative payments that are
not visit-related, and the algorithms also ascribe those
payments, generally on an average per-patient approach.
Capitation payments are calculated based on the pay-
ment rate and the particular model of primary care for
each patient’s physician in each month of the study
period. Team-based payments for family health teams
and physician bonus payments for pay-for-performance
are not ascribed to individual patients and thus are not
included in the analysis.
Data analysis
All data will be analyzed according to an intention to
treat principle. Patient characteristics and baseline
HbA1c levels will be summarized using descriptive
statistics, including means, quartiles and standard devia-
tions for continuous variables and proportions for
categorical variables. The primary outcome, HbA1c
levels between treatment groups, will be analyzed using
an analysis of covariance (ANCOVA) with follow-up at
three months. PROMs and PREMs will be analyzed
using an ANCOVA evaluated at 3 months as well.
Continuous secondary outcomes including emergency
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department visits, physician visits, and hypoglycemic
episodes will be analyzed using Poisson regression
predicted with the two treatment groups. Ordinal cat-
egorical variables including medication adherence and
frequency of glucose monitoring will be analyzed
using an ordinal regression model for the two treat-
ment groups. We will use regression analyses to
separately estimate the difference in healthcare costs
between the intervention and control groups and
include any covariates that are observed to be differ-
ent between groups in baseline comparisons. To iden-
tify the regression model that fits best with the cost
data and potential skew, we will follow the steps sug-
gested by Manning and Mullahy [30] to decide
between regression on transformed cost data or gen-
eralized linear models.
Six-month follow-up data for the immediate treat-
ment group will be analyzed descriptively. In addition,
HbA1c levels will be compared at the 6-month point
between the two treatment groups using an ANCOVA
which will control for baseline HbA1c levels. Applica-
tion utilization data will be analyzed descriptively,
including time (mean duration of use), general fre-
quency of use (mean uses per week), and frequency
of use for each application feature. Subgroup analyses
based on site and patient demographics, including
age, sex, ethnicity, education, and income [31], will
also be conducted. All statistical analyses will be per-
formed using R version 3.0.3 (The R Foundation for
Statistical Computing; Vienna, Austria).
Power calculation
Power was determined assuming an ANCOVA analysis
with an estimate correlation between baseline and
follow-up HbA1c measurements of 0.80. The power to
detect a difference of 0.7 % [32] in HbA1c levels using a
standard deviation of 2 % [32] between treatment groups
at 3 months is 0.997 with an alpha of 0.05 based on a
sample size of 255 (which assumes a dropout rate of
15 % from the target sample size of 300 participants).
Embedded process evaluation
Many effective health services interventions fail to be
widely adopted or translated into real-world practice
[33, 34]. Given that innovations in health services are in-
evitably complex interventions, “an understanding of the
causal assumptions underpinning the intervention and
use of evaluation to understand how interventions work
in practice are vital in building an evidence base that
informs policy and practice” 35 (p.1). The UK Medical
Research Council’s Guidelines for Process Evaluation
of Complex Interventions [35] provides a framework
for such evaluations and has directly informed the
current evaluation.
The embedded process evaluation involves a qualita-
tive approach using observation and individual semi-
structured interviews to evaluate how and why the
intervention achieved the effects observed, if any. Using
an embedded single case design with cross case synthe-
sis, the objective of the process evaluation is to gain an
in-depth understanding of intervention fidelity, the
Fig. 3 Modified Mobile Application Rating Scale
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mechanisms of action, and the conditions and factors as-
sociated with implementation of the intervention. We
will conduct observations of the initial education and
training provided to healthcare providers around the
purpose of the application and how to interact with it.
Qualitative observations will involve a researcher sitting
in on the training and taking detailed notes regarding
when and how the application is introduced, questions
asked, and how participants interact with the technology
during the training session [36]. Two observations of
1–2 h in length will take place at each health care site
with the aim of capturing the processes and strategies
used to introduce the application to patients. Notes will
record details around how the application is described
to patients/caregivers, any questions asked by patients/
caregivers, and the actions taken to explain the use of
the application or to practice using the technology itself
(where feasible).
To evaluate intervention fidelity and understand the
mechanisms of action, we will interview individuals from
each implementation site, guided by the principles of
Realist Evaluation. Realist Evaluation seeks to under-
stand what works, for whom, under what circumstances
[37], and will provide crucial insight into the contextual
conditions in each clinical and regional setting that sup-
port or hinder the success of the intervention in each
specific patient group. In order to capture a range of
perspectives impacting the implementation of the inter-
vention, we will seek to interview participants and their
caregivers, as appropriate; healthcare providers who
interact with study participants and the application;
organizational administrators who oversee the imple-
mentation process at each site; and health system deci-
sion makers involved in the implementation of e-Health
initiatives in Ontario.
Recruitment
Participants and caregivers Participants will be in-
formed of the qualitative process evaluation at the time
of enrollment. A sub-sample of participants who indicate
interest will be invited to participate in the semi-structured
Table 1 Databases and cost components used in the calculation of health system costs before, during, and after cancer treatment
Database Description Cost component
Ontario Health Insurance Plan
and (OHIP)
Contains claims paid by OHIP for services provided by all eligible health care
providers, including physicians, groups, and laboratories.





Contains data from hospital- and community-based ambulatory care services,
including day surgery, outpatient clinics, and emergency departments.
• Emergency department visits
• Dialysis visits
• Oncology clinic visits
Discharge Abstract Database Contains information on patient separations, notably:
• clinical data (diagnoses, procedures)
• administrative data (institution information, admission type, length of stay, disposition)




Registry of patients enrolled in a primary care model. Data elements include program
type (family health team, family health organization, family health network, etc.) and
patient enrolment status.
• Capitation costs
Ontario Drug Benefit and
(ODB)
Contains claims for prescription drugs covered under the ODB program. Primarily
includes drug claims for individuals 65 years of age and older, but also coverage




Contains client data from adult inpatient rehabilitation facilities, such as
• administrative data (referral, admission, and discharge);
• health and functional characteristics;






Contains information about residents receiving facility-based continuing care services.
Range of services includes complex continuing care, extended or chronic care, and
residential care providing nursing services (that is, long-term care).
• Complex continuing care
admissions and long-term care
Home Care Database Captures information on all services provided or coordinated by Ontario Community
Care Access Centres, including client data, intake and assessment information, admission
and discharge, diagnosis and procedures, and care delivery.
• Home care services
Ontario Mental Health and
Reporting System
Contains data on patients in adult designated inpatient mental health beds in acute and
psychiatric facilities. Data elements include admission and discharge information, diagnoses,
service utilization or intervention and procedures.
• Mental health admissions
Assistive Devices Program Contains data on Ontario residents with long-term disability receiving personalized assisted
devices to support basic needs, such as insulin pumps and supplies, home oxygen, and
respiratory and ventilator equipment.
• Assistive devices
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interviews. Participants will be selected to maximize sam-
pling variation, including baseline HbA1c, socioeconomic
status, ethnicity, and age. Participants with a caregiver will
be given the option whether or not to include their care-
giver in the interviews. Participants will be invited to
participate in two interviews (refer to Fig. 1): an interview
at baseline (within 2–4 weeks of study enrolment), and a
follow-up interview towards the end of the study (within
4–6 months of study enrolment).
Healthcare providers All healthcare providers involved
in direct patient care at participating DEPs will be sent a
letter of information outlining the objectives of the
qualitative interviews. A member of the research team
will contact those individuals expressing interest, provid-
ing additional information as needed and obtaining
informed consent.
Organizational administrators and health system
decision makers The project coordinator at each DEP
will help the research team identify key administrators
involved in supporting the implementation of the inter-
vention. The project contact at OTN will identify key
health system decision makers involved in the selection,
procurement, and implementation of e-Health technolo-
gies into the health care system. We will use snowball
sampling by asking interview participants in each group
to identify other individuals within the organization who
are involved in the processes around the selection, pro-
curement, implementation, and ongoing support of
e-Health technologies.
Data collection
Semi-structured interview guides include questions that
cover the following general topics, guided by the princi-
ples of Realist Evaluation [37]. Topics include partici-
pants’ experiences of learning about and using the
technology; changes to health care provider workflow
required to effectively use the technology; organizational
changes required to support the technology; and health
system barriers and facilitators to effective implementa-
tion and evaluation (please contact the authors for
copies of each respective interview guide). The interview
guides were pilot tested on healthcare providers and re-
searchers to ensure clarity and relevance to the over-
arching research questions. No substantial changes were
made to the interview guides during this process. If
needed, interview guides will be refined iteratively fol-
lowing individual interviews based on the feedback from
participants and the experiences of the interviewers. It is
expected interviews will last between 30 and 60 min. In-
terviews will be audio recorded and transcribed verbatim
by an external third party.
Data analysis
Written observations and qualitative interviews will be
immediately transcribed into word documents and
prepared for qualitative analysis. Observations will also
be analyzed using thematic analysis strategies [37, 38],
identifying key themes that demonstrate important con-
textual influences and practices related to the implemen-
tation and evaluation of the e-Health technologies in
actual contexts of health care delivery. A minimum of
two reviewers will independently code all transcripts
using an open coding process. Following the first five
interviews, a coding schema will be created to guide the
analysis of subsequent interviews. Open coding will be
applied throughout the analysis for content that does
not fit within the coding schema. Consolidation of codes
and resolution of any disagreements will be achieved
through consultation with a third reviewer.
After the thematic analyses of all qualitative data has
been completed, the key themes identified will be com-
pared against the implementation and rapid evaluation
framework developed in the first phase of the study. The
findings of the qualitative data will be used to develop
statements of the relationships between (a) key context-
ual factors, (b) the mechanisms by which they affect the
implementation of the e-Health interventions, and (c)
the impact on the outcomes of the intervention
themselves (in Realist Evaluation these statements are
referred to as “Context-Mechanism-Outcome Configura-
tions”) [37]. These statements will then be used to revise
the framework in order to more accurately reflect the
key contextual influences and practices that constitute
the implementation process in actual health care settings
in Ontario.
Limitations
Aspects of the study design limit the generalizability of
the study results, including a short follow-up period and
the restriction of participant sampling to DEPs, where
complexity of patients with T2DM may be lower. In
addition, effectiveness cannot be generalized to other
relevant clinical outcomes beyond glycemic control (e.g.,
blood pressure and lipid levels). Required proficiency in
the English language limits generalizability beyond this
cohort of individuals and the pragmatic nature of this
trial. Study participants receive a unique smartphone to
enable participation in the study, which may be unfamil-
iar and pose a challenge when trying to integrate its use
into established routines; however, in contrast, providing
a unique device to study participants also increases
intervention access for those individuals who do not
currently own a smartphone.
If the provision of phones is not included in potential
plans to scale-up the intervention (if successful), the
pragmatic nature of this trial and its generalizability are
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limited. Furthermore, as cost estimates will not include
the cost of the phones and additional staff required to
implement the intervention, subsequent scale-up activ-
ities need to acknowledge this limitation by including
these costs in their scale-up models or assuming a nat-
ural penetration estimate for smartphone use in a given
clinical population. As a study-specific phone was pro-
vided to all participants, those already in possession of a
phone were required to utilize both phones, which may
negatively impact the ecological validity. As a result, the
impact of carrying two phones will be explored in the
qualitative evaluation. The mobile application was devel-
oped in an American context with different guideline
recommendations, which may influence its utility and
effectiveness in a Canadian context. Finally, it is un-
certain how findings will be able to be generalized
from this specific evaluation to apply to other mobile
applications design to improve self-management for
individuals with T2DM.
Discussion
Web and mobile-based platforms for self-management
interventions are promising as they can improve patient
knowledge, and clinical outcomes [39] while being scaled
to improve access for patients who are computer-literate
at little cost [40]. This is particularly important for
providing care for individuals with diabetes, where self-
management plays a pivotal role to improve health
outcomes. Mobile-based interventions to enhance self-
management provide increased flexibility, convenience,
and patient access [32] and leverages the fact that three
out of four Canadians own a personal smartphone [41].
Results of this trial will provide much needed informa-
tion about the clinical- and cost-effectiveness of the
mobile application. As the application was developed
and evaluated in the United States, this study aims to
evaluate the application’s potential to improve diabetes
self-management in the Canadian context. The process
evaluation fills a gap in the literature, providing valuable
insight into the contextual factors that influence the ef-
fectiveness of the application. The results of the process
evaluation will inform considerations around whether
and how to scale-up the intervention system-wide and
enhances the translational aspect of this work. This
aspect of the evaluation will have significant implications
for healthcare administrators, government agencies, and
other stakeholders interested in the use of e-Health
technologies to improve health status and patient experi-
ence alongside system-level outcomes.
Trial status
The trial is actively recruiting participants across all
three sites. A total of 14 participants have been
recruited to date.
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